17.18

0.67% -0.03

Y-Mabs Therapeutics Inc (YMAB)

Overview News Price History Option Chain Financials Discussions Forecast

Y-Mabs Therapeutics Inc stock is currently priced at $17.18, with a 24-hour trading volume of 43,057. It has seen a -0.67% decreased in the last 24 hours and a +17.81% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $17.30 pivot point. If it approaches the $16.83 support level, significant changes may occur.

Previous Close:

$17.15

Open:

$17.15

24h Volume:

43,057

Market Cap:

$752.42M

Revenue:

$84.82M

Net Income/Loss:

$-21.43M

P/E Ratio:

-19.30

EPS:

-0.89

Net Cash Flow:

$-27.23M

1W Performance:

+9.90%

1M Performance:

+17.81%

6M Performance:

+196.26%

1Y Performance:

+146.53%

1D Range:

$16.80

$17.29

52W Range:

$4.60

$20.90

Y-Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name

Y-Mabs Therapeutics Inc

Sector

Healthcare (1215)

Industry

Biotechnology (699)

Phone

212-847-9841

Address

230 Park Avenue, 33rd Floor, New York, NY

Employee

Twitter

Next Earnings Date

2024-05-08

Latest SEC Filings

YMAB's Discussions on Twitter

Y-Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-10-23	Upgrade	Wedbush	Neutral → Outperform
Apr-03-23	Downgrade	Guggenheim	Buy → Neutral
Jan-27-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-05-23	Downgrade	Cowen	Outperform → Market Perform
Dec-02-22	Downgrade	BofA Securities	Buy → Neutral
Oct-31-22	Downgrade	JP Morgan	Neutral → Underweight
Oct-31-22	Downgrade	Wedbush	Outperform → Neutral
Jul-06-22	Resumed	Canaccord Genuity	Buy
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Feb-03-22	Resumed	Guggenheim	Buy
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Nov-16-21	Downgrade	JP Morgan	Overweight → Neutral
May-07-21	Upgrade	BofA Securities	Neutral → Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-22-21	Resumed	JP Morgan	Overweight
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral
Nov-09-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Overweight
May-01-20	Initiated	Janney	Buy
Apr-29-20	Initiated	Morgan Stanley	Equal-Weight
Dec-24-19	Initiated	JP Morgan	Overweight
Nov-20-19	Initiated	Guggenheim	Buy
Sep-04-19	Initiated	Wedbush	Outperform
Apr-01-19	Initiated	H.C. Wainwright	Buy
Oct-16-18	Initiated	BTIG Research	Buy
Oct-16-18	Initiated	BofA/Merrill	Buy

View All

Y-Mabs Therapeutics Inc Stock (YMAB) Latest News

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

GlobeNewswire Inc.

Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet

Zacks Investment Research

YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?

Zacks Investment Research

Y-Mabs Therapeutics Inc Stock (YMAB) Financials Data

Y-Mabs Therapeutics Inc (YMAB) Revenue 2024

YMAB reported a revenue (TTM) of $84.82 million for the quarter ending December 31, 2023, a +29.96% rise year-over-year.

Y-Mabs Therapeutics Inc (YMAB) Net Income 2024

YMAB net income (TTM) was -$21.43 million for the quarter ending December 31, 2023, a +77.58% increase year-over-year.

Y-Mabs Therapeutics Inc (YMAB) Cash Flow 2024

YMAB recorded a free cash flow (TTM) of -$27.23 million for the quarter ending December 31, 2023, a +64.13% increase year-over-year.

Y-Mabs Therapeutics Inc (YMAB) Earnings per Share 2024

YMAB earnings per share (TTM) was -$0.49 for the quarter ending December 31, 2023, a +77.52% growth year-over-year.

Y-Mabs Therapeutics Inc Stock (YMAB) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Rajah Vignesh	SVP & CHIEF MEDICAL OFFICER	Mar 05 '24	Sale	16.53	1,711	28,283	33,889
Smith Susan Laura	SVP & CHIEF COMMERCIAL OFFICER	Mar 05 '24	Sale	16.55	1,682	27,837	33,918
Gad Thomas	Chief Business Officer	Dec 21 '23	Option Exercise	2.00	50,000	100,000	140,500
Gad Thomas	Chief Business Officer	Dec 15 '23	Sale	6.61	50,000	330,500	265,032
Gad Thomas	Chief Business Officer	Dec 14 '23	Sale	6.83	50,000	341,500	315,032
Gad Thomas	Chief Business Officer	Dec 13 '23	Sale	6.58	50,000	329,000	365,032
Wedell-Wedellsborg Johan	Director	Dec 11 '23	Buy	7.01	102,863	720,843	4,552,778
WG Biotech ApS	Director	Dec 11 '23	Buy	7.01	102,863	720,843	4,552,778
Wedell-Wedellsborg Johan	Director	Dec 11 '23	Buy	6.85	6,455	44,232	4,559,233
WG Biotech ApS	Director	Dec 11 '23	Buy	6.85	6,455	44,232	4,559,233

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.